Skip to content

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07636148
Acronym
PreciseOnco
Enrollment
2000
Registered
2026-06-09
Start date
2026-07-01
Completion date
2030-12-31
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Cancer Metastatic, Bone Cancer Tumor, Bone Tumors, Hepatocellular Carcinoma (HCC), Kidney Tumors, Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Lung Tumors, Musculoskeletal Cancers, Musculoskeletal Tumors, Renal Cancer, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC)

Keywords

Spectral CT, Dual-layer detector CT, Angio-CT, Image-guided therapy, Interventional oncology, Thermal ablation, Radiofrequency ablation, Microwave ablation, Cryoablation, Transarterial chemoembolization, Transarterial radioembolization, Transarterial embolization, Local tumor control, Tumor recurrence, Progression-free survival, Hepatocellular carcinoma, Liver metastases, Renal cell carcinoma, Lung tumors, Musculoskeletal tumors, Registry, Multicenter

Brief summary

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone. During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results. No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Detailed description

Interventional oncology (IO) is an established component of cancer care, offering minimally invasive, image-guided treatments for solid tumors in organs such as the liver, kidney, lung, and musculoskeletal system. IO procedures include percutaneous techniques such as thermal ablation, as well as catheter-based approaches such as transarterial embolization, chemoembolization, and radioembolization. Compared to surgical approaches, these procedures are associated with lower morbidity and mortality, shorter hospital admissions, and lower costs. Medical imaging plays a central role throughout the IO workflow, from diagnosis and treatment planning to procedural guidance and post-treatment assessment. One major advancement in this context is the integration of angiography and CT into a single angio-CT system, allowing seamless transitions between real-time fluoroscopy and high-resolution cross-sectional imaging during procedures. The newest generation of angio-CT systems incorporates spectral CT technology, which enables energy-resolved imaging through dual-layer detector technology. This simultaneously acquires spectral data while providing conventional CT reconstructions, allowing standard workflow and image interpretation to remain unchanged while spectral information is available as additional imaging data. Spectral CT has the potential to enhance lesion detection and tissue characterization, reduce metal artifacts, and improve the accuracy of treatment evaluation compared with conventional CT. All procedures are performed according to standard clinical care at the participating centers. Study participation does not influence clinical decision-making, treatment strategy, or follow-up. No experimental interventions are performed. This is a prospective, observational, multicenter, international registry study coordinated by Leiden University Medical Center (LUMC). Participating centers include Leiden University Medical Center (LUMC, the Netherlands), Hospices Civils de Lyon (HCL, France), and Assistance Publique Hôpitaux de Paris (APHP, France). The study is part of the EU-funded PreciseOnco project, which aims to further integrate and optimize imaging and guidance technologies within clinical IO workflows.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
CollaboratorOTHER
Philips GmbH Innovate Technologies
CollaboratorUNKNOWN
Quantum Surgical
CollaboratorINDUSTRY
IGEA
CollaboratorINDUSTRY
Hospices Civils de Lyon
CollaboratorOTHER
Mark C Burgmans, MD PhD
Lead SponsorOTHER
European Commission
CollaboratorOTHER
Philips Medical Systems
CollaboratorINDUSTRY
Philips Electronics Nederland BV
CollaboratorINDUSTRY
Philips France Commercial
CollaboratorINDUSTRY
EIBIR - European Institute for biomedical imaging research
CollaboratorUNKNOWN
Cardiovascular and Interventional Radiological Society of Europe
CollaboratorOTHER
Klinikum der Universität Köln
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years; * Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors; * Use of spectral angio-CT image guidance as part of standard care; * Written confirmed consent.

Exclusion criteria

* Patients who are declared incapacitated; * Patients suffering from psychic disorders that make a comprehensive judgement impossible.

Design outcomes

Primary

MeasureTime frameDescription
Local tumor control6 months, 1 year, 2 years, 3 yearsLocal tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.

Secondary

MeasureTime frameDescription
Overall survival6 months, 1 year, 2 years, 3 yearsTime from the index procedure to death from any cause.
Progression-free survival6 months, 1 year, 2 years, 3 yearsTime from the index procedure to disease progression or death from any cause.
Ablation margin and embolization completenessAt time of procedureAssessment of ablation margins and completeness of embolization using spectral CT imaging, compared to standard CT reconstructions.
Incidence of periprocedural adverse events30 days after procedurePeriprocedural complications and adverse events graded according to the Common Terminology Criteria for Adverse Events version 6 (CTCAEv6).
Procedure durationAt time of procedureDuration of the procedure to evaluate the workflow.

Countries

France, Netherlands

Contacts

CONTACTEmma C.M. Buijsman, MSc
e.c.m.buijsman@lumc.nl+31 71 526 49 50

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026